logo
Faith, family and friendship on display at Dowling Catholic as Foth family fights childhood cancer repercussions

Faith, family and friendship on display at Dowling Catholic as Foth family fights childhood cancer repercussions

Yahoo07-05-2025

DES MOINES, Iowa — Faith, family, and friendship were on full display at Dowling Catholic High School Tuesday night as one of their own families fights the repercussions of childhood cancer.
Ava Foth, a sophomore at the school, underwent a bone marrow transplant on Tuesday. Ava was diagnosed with bone cancer in 2022. The treatment was successful, but Ava developed Myelodysplastic Syndrome, a rare form of cancer that comes from cancer treatment and impacts the bone marrow.
John and Ava Foth were both recovering in the children's hospital on Tuesday.
Her brother, John, a senior at the school and captain of the varsity soccer team, found out he was a bone marrow donor match for Ava, and did not hesitate to volunteer. His bone marrow was harvested in a procedure on Monday, roughly 24 hours before it was transplanted into Ava. That has caused him to miss out on leading his team for several games.
Despite the family being at the University of Iowa Stead Family Children's Hospital in Iowa City on Tuesday night, the school honored them during the 7:30 p.m. varsity soccer home game.
Dozens of rescued bats released back into the wild in Des Moines
'It's feels good to know that people are checking in, and they care about us and they are praying for us,' said Michelle Foth, as she held back tears. 'It's kind of hard to put into words everything they're doing to surround our family with love and support.'
Michelle spoke to WHO 13's Katie Kaplan via FaceTime from John's hospital room. The mother and son had been able to see how their school community was honoring them through the lens of a friend's cell phone.
'In this family, no one fights alone,' said one sign that greeted people as they entered the stadium. The evening included free yellow ribbons for spectators (a symbol of bone cancer), signs of encouragement for Ava and John, the entire team warming up in specialty shirts bearing John's team number, and lots of prayers.
'The support is great, but it's Ava, who's going through this,' said John, who was sore but in good spirits during his recovery.
The crowd also participated in a symbolic wave, which mirrored a Hawkeye football tradition where fans in the University of Iowa's Kinnick Stadium wave to patients and families at the children's hospital just across the street.
'It's been really hard to watch them struggle through this,' said Blythe Stanfel, a close friend of Michelle's. 'But we know that they have faith and (sic) that God has a plan, and they're they're trusting and they're hoping and just relying on the Lord.'
'The whole family, they are so nice,' said John's former co-captain Henry Abaraca. 'Some of the nicest people I've ever met.'
Abaraca graduated last year, but has remained close with John. He said he would often play video games with Ava during her first cancer treatment to help pass the time in the hospital, and said he was happy to support the family in any way he could.
'I'm glad that I can help her just kind of, you know, feel free and not have to worry about all the stuff that's going on, he said.
Michelle said Ava's transplant, which had taken place only a few hours prior, had gone well and that the next few weeks ahead would be focused on recovery for both children.
'We'll be here in the hospital for quite some time,' said Michelle. 'We'll just do everything we can to keep her healthy and safe.'
The Foth family encourages people to look into the donor registry. All it takes is one swab to see if you are a match to save a life. To sign up to be a bone marrow donor, visit the National Marrow Donor Program Website.
Metro News:
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to who13.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Healthcare Simulation Market worth US$7.23 billion by 2030 with 15.6% CAGR
Healthcare Simulation Market worth US$7.23 billion by 2030 with 15.6% CAGR

Yahoo

timea day ago

  • Yahoo

Healthcare Simulation Market worth US$7.23 billion by 2030 with 15.6% CAGR

DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ -- The global Healthcare Simulation Market, valued at US$3.00 billion in 2024 stood at US$3.50 billion in 2025 and is projected to advance at a resilient CAGR of 15.6% from 2025 to 2030, culminating in a forecasted valuation of US$7.23 billion by the end of the period. This growth is likely to be driven by rising demand for standardized clinical training, increasing prevalence of chronic diseases, higher investment in healthcare technology, and more medical and nursing schools adopting simulation. Key contributors include patient simulators, interventional and cardiac surgical simulators, and simulation training services. Adoption is growing in hospitals and academic institutions, especially in North America and Asia Pacific. Governments are also supporting simulation-based training. For example, the University of Iowa received a USD 8-million grant from the Helmsley Charitable Trust to launch SIM-IA, a mobile simulation program for rural healthcare providers and first responders. Download PDF Brochure: Browse in-depth TOC on "Healthcare Simulation Market" 150 - Tables50 - Figures359 - Pages By Based on product & service, the healthcare simulation market, by product & service, is segmented into healthcare simulation anatomical models, healthcare simulation software, web-based simulation, and simulation training services. In 2024, the anatomical models accounted for the largest market share, driven by the increasing emphasis on patient safety and hands-on clinical training. These models allow medical students and professionals to practice procedures in a realistic, risk-free environment, enhancing clinical skills and reducing medical errors. As healthcare systems aim to improve efficiency and reduce costs, anatomical models are widely adopted as cost-effective alternatives to traditional training with live patients. Furthermore, the rising demand for minimally invasive procedures, ongoing advancements in surgical techniques, and growing funding for simulation-based education continue to boost their adoption in academic institutions and healthcare facilities, solidifying their position as the leading segment in the market. By Based on technology, the healthcare simulation market is segmented by technology into virtual patient simulation, 3D printing, and procedural rehearsal technology. Among these, the virtual patient simulation segment is expected to register the fastest growth rate during the forecast period due to its ability to provide immersive, risk-free, and repeatable training experiences for healthcare professionals. Leveraging virtual reality (VR) and augmented reality (AR) enables learners to practice clinical scenarios, decision-making, and patient interactions in highly realistic environments. This technology is particularly valuable for training in complex or rare medical cases that are difficult to encounter in real life. Several recent developments underscore this trend. For instance, in November 2024, VRAD Co., Ltd. launched NS_Core and IP_Trauma—two VR-based simulators for nursing and trauma care. Moreover, in July 2024, MediSim VR and KD Hospital opened India's first VR nurse training lab to enhance clinical skills through immersive simulation. These developments highlight the growing strategic focus on virtual patient simulation as a transformative tool in modern medical education and clinical training. By geography, in 2024, North America led the healthcare simulation market, mainly driven by sustained investments in mobile simulation technology and rural healthcare training. Notable initiatives include Washington State University's Mobile Simulation Program, launched in June 2024; the Simulation in Motion–Iowa (SIM-IA) program, launched in June 2022; and the Parkview Health Mobile Medical Training Lab (Indiana, USA), launched in May 2024. These programs are specifically designed to address the needs of underserved and rural communities, delivering high-fidelity simulation training directly to local healthcare providers. Such initiatives exemplify North America's commitment to expanding equitable access to simulation-based education. Furthermore, strong collaborations between academic institutions and healthcare systems, robust government support through initiatives such as the Health Resources and Services Administration (HRSA) grants, federal and state funding for mobile simulation units, and significant philanthropic funding have positioned North America as a global leader in healthcare simulation. These combined efforts enhance clinical preparedness, improve healthcare delivery, and ultimately strengthen patient outcomes across the region. Request Sample Pages : The key players functioning in the healthcare simulation market include CAE Inc. (Canada), Laerdal Medical (Norway), Gaumard Scientific Co. (US), Kyoto Kagaku (Japan), Limbs & Things (UK), Mentice AB (Sweden), Simulab Corporation (US), Simulaids (US), Intelligent Ultrasound Group PLC (UK), and Operative Experience Inc. (UK), and Surgical Science Sweden AB (Sweden), among others. CAE Inc. (Canada): CAE Inc. is a leader in simulation and training technologies, with a specialized Healthcare division offering high-fidelity patient simulators, ultrasound simulators, pediatric simulators, and surgical simulation systems. The company operates globally across 80+ countries, leveraging direct and partner-driven channels. CAE's core competencies include AR/VR integration, haptic feedback, and simulation center management. Major activities include strategic partnerships, acquisitions (e.g., Medicor), and R&D investments. CAE focuses on developing innovative training solutions, such as Vimedix and LucinaAR, and supports simulation research through collaborations with global universities, enhancing clinical skills and patient outcomes. Laerdal Medical (Norway) Laerdal Medical specializes in simulation-based training to improve patient outcomes, offering high-fidelity patient simulators, CPR manikins, and task trainers. The company's core competencies lie in scalable digital learning, resuscitation, and trauma care training. Major activities include acquisitions (e.g., B-Line Medical) and partnerships (e.g., SimX for VR simulation). Laerdal strongly focuses on innovation and adaptive learning, collaborating with global organizations such as the American Heart Association and GAVI. These initiatives enable Laerdal to lead in digital healthcare education and significantly advance clinical competency and patient safety. For more information, Inquire Now! Related Reports: Healthcare Education Market Healthcare Analytical Testing Services Market Healthcare IT Market Healthcare Analytics Market Remote Patient Monitoring Market Get access to the latest updates on Healthcare Simulation Companies and Healthcare Simulation Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio

Measles in Iowa: What parents, and the public, should know about the first case in nearly six years
Measles in Iowa: What parents, and the public, should know about the first case in nearly six years

Yahoo

time2 days ago

  • Yahoo

Measles in Iowa: What parents, and the public, should know about the first case in nearly six years

DES MOINES, Iowa — The first confirmed case of measles in Iowa since 2019 was announced by the state's Department of Health and Human Services on May 23, 2025. However, specific details on the patient and potential exposure of additional residents have been limited. 'Through our thorough investigation, it was learned this individual had traveled outside of the state of Iowa,' said HHS's Director of Communications Alex Murphy via email to WHO 13's Katie Kaplan. 'A thorough investigation has been completed. Public health officials will be reaching out to identified contacts, and no widespread public exposure is anticipated.' While the initial release from HHS on the confirmed Iowa case stated the patient was an unvaccinated adult, Murphy added that any further information about the specifics of the case was 'protected from disclosure under Iowa Code 139A.3(3).' While it is unconfirmed which medical facility the patient was treated at, WHO 13 was able to view internal messages from Central Iowa medical networks that were sent to area medical professionals. One noted that the Central Iowa resident may have recently traveled to Mexico and Texas. HHS confirmed to WHO 13 that the patient traveled internationally, but did not specify where. The announcement about the highly contagious viral illness that is spread through the air when an infectious person coughs, sneezes, or breathes was made late in the workday on a Friday afternoon before the Memorial Day weekend. 'Measles is as scary as it sounds because it's so contagious,' said Dr. Daniel Pelzer, a Pediatrician with the Iowa Clinic. 'It is 10 to 12 times more contagious than a normal flu virus that spreads around every year. And for that reason, it's important for us to get ahead of that so that the unvaccinated or under-vaccinated in our community aren't at risk.' Pelzer said local physicians have been following the growing number of cases across the U.S. and have been preparing for a local case for months. He added that the case, which HHS said tested positive at the State Hygienic Laboratory, activated the plans that include vetting patients through their symptoms, limiting exposure to the public, and the potential use of hazmat, or PPE (Personal Protective Equipment) gear, for health providers. He said the first step the public should take if they believe they have the measles, or have been exposed to the illness, is to pick up the phone. Des Moines police release name of motorcyclist killed in crash 'For parents, if you think you have a case of measles in your house, or a known exposure, call us. Again, measles is so contagious that if it would arrive in our office, it would grind the entire clinic to a halt because of the density of airborne virus transmission,' he said. According to the HHS, about 1 in 10 people in the U. S. who get measles will be hospitalized, and 1 to 3 out of 1,000 children with measles will die even with good medical care. Measles was declared 'eliminated' from the United States in 2000, according to the CDC. This meant the absence of the continuous spread of disease was greater than 12 months. Most people who have been fully vaccinated against the illness do not need booster shots and are 'less susceptible' to contracting it, Pelzer said. However, he said he has watched as immunizations in local children have fallen in recent years, specifically since the Pandemic. 'Herd immunity, about 95%, is what we need to effectively, in communities, limit the spread of measles,' he said. 'In the last decade that I've been a pediatrician in this town, I've seen that rate decrease from 95%, which is our safe rate, down to closer to 90% by our best guesses.' Measles symptoms include a high fever, cough, and runny nose, followed by a red rash most often found on the face and arms. Tiny white bumps may also develop inside the mouth. The illness can lead to swelling of the brain and other complications. 'The best time to prevent measles is before an exposure occurs, and the best tool we have is getting the measles, mumps, and rubella (MMR) vaccine,' said Dr. Robert Kruse, State Medical Director, via a written statement provided by the HHS. 'Getting vaccinated not only protects you but also protects people in your community who can't get vaccinated, like infants too young to begin the series and those who are immunosuppressed.' If you think you have been exposed to a measles case and have symptoms, call your medical provider or nearest emergency room ahead of time and tell them that you have been exposed to measles and have symptoms before arriving. Measles symptoms begin to appear 7-to-21 days after exposure. As of June 5, nearly two weeks after the announcement of the case, the HHS told WHO 13 that there have been no other confirmed cases of measles in the state of Iowa. Iowa News: Measles in Iowa: What parents, and the public, should know about the first case in nearly six years WHO 13 Farm Report: Thursday, June 5 Motorcyclist killed after being hit by semi in Floyd County identified Forecast: Mild temps and tiny rain chances WHO 13 Farm Report: Wednesday, June 4 Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Myelodysplastic Syndrome Competitive Landscape 2025: 262 Molecules in MDS Pipeline - A Peek into Future Therapeutics
Myelodysplastic Syndrome Competitive Landscape 2025: 262 Molecules in MDS Pipeline - A Peek into Future Therapeutics

Yahoo

time2 days ago

  • Yahoo

Myelodysplastic Syndrome Competitive Landscape 2025: 262 Molecules in MDS Pipeline - A Peek into Future Therapeutics

Discover the competitive landscape of Myelodysplastic Syndrome (MDS) therapeutics. With 498,757 cases in 2024 and a slight increase by 2029, the report reveals a robust pipeline of 262 molecules and over 1,200 clinical trials. Uncover key market players, future catalysts, and strategic insights for effective market positioning. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndrome: Competitive Landscape" report has been added to reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. The analyst epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87 assets in Phase II. Over the past decade, 1,229 clinical trials have been conducted in MDS. During the past decade, partnerships were most prevalent in North America and Europe. Report ScopeThe Myelodysplastic Syndrome Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease of the report include: Disease Landscape Disease Overview Epidemiology Overview Treatment Overview Marketed Products Assessment Breakdown by Mechanism of Action, Route of Administration Product Profiles with Sales Forecast Pricing and Reimbursement Assessment Annual Therapy Cost Time to Pricing and Time to Reimbursement Pipeline Assessment Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Late-to-mid-stage Pipeline Drugs Phase Transition Success Rate and Likelihood of Approval Clinical Trials Assessment Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status Enrolment Analytics, Site Analytics, Feasibility Analysis Deals Landscape Mergers, Acquisitions, and Strategic Alliances by Region Overview of Recent Deals Commercial Assessment Key Market Players Future Market Catalysts Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the Myelodysplastic Syndrome Therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myelodysplastic Syndrome Therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market CatalystsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store